Trends and Patterns of Tobacco and Nicotine Product Use Among Youth in Canada, England, and the United States From 2017 to 2019.
Adolescent
Electronic nicotine delivery systems
Nicotine
Prevalence
Smoking
Surveys and questionnaires
Tobacco products
Journal
The Journal of adolescent health : official publication of the Society for Adolescent Medicine
ISSN: 1879-1972
Titre abrégé: J Adolesc Health
Pays: United States
ID NLM: 9102136
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
03
12
2020
revised:
17
02
2021
accepted:
17
02
2021
pubmed:
12
4
2021
medline:
28
10
2021
entrez:
11
4
2021
Statut:
ppublish
Résumé
The tobacco and nicotine market is diversifying. Implications for public health will depend on trends in use, including overall use, and who is using these products. This study examined differences over time (2017-2019), across countries (Canada, England, the United States (US)), and by smoking and vaping, in use of other tobacco/nicotine products and overall use. The study includes online repeat cross-sectional surveys of youth aged 16-19 years in Canada (N = 11,714), England (N = 11,170), US (N = 11,838) in 2017, 2018, and 2019. Past 30-day use of tobacco/nicotine products (any, cigarette, e-cigarette, other combusted [cigars/cigarillos/waterpipe], other non-combusted [smokeless tobacco/nicotine replacement therapies) were examined by country, year, and, for other combusted and non-combusted products, past 30-day cigarette smoking and vaping. Use of emerging products (IQOS, nicotine pouches) was explored in 2018-2019. From 2017 to 2019, use of any product increased in Canada (17.1%-23.2%, AOR = 1.07 [95% CI = 1.04-1.09]) and the US (18.0%-24.0%, AOR = 1.06 [1.04-1.09]) but not England (20.8%-21.7%, AOR = 1.01 [.99-1.03]). Use of other combusted products (cigars/cigarillos/waterpipe) showed little change (Canada: 8.1%-7.8%; England: 6.3%-7.3%; US: 8.6%-8.5%; p ≥ .151). Use of other non-combusted products (smokeless/nicotine replacement therapies) increased in all countries (Canada: 1.5%-3.2%, AOR = 1.02 [1.01-1.02]; England: 1.4%-2.6%, AOR = 1.02 [1.01-1.03]; US: 3.3%-4.9%, AOR = 1.02 [1.01-1.02]). Vaping increased in all countries (Canada: 8.4%-17.8%; England: 8.7%-12.6%; United States: 11.1%-18.5%; all p < .001). Smokers and vapers reported greater use of other combusted and non-combusted products than those who neither smoked/vaped (p < .001). Emerging product use was rare (≤1.5%). Youth past 30-day tobacco and nicotine product use increased from 2017 to 2019 in Canada and the United States, largely due to increases in vaping and other non-combusted products. "Other" tobacco/nicotine products were used predominantly by youth who smoked cigarettes and/or vaped.
Identifiants
pubmed: 33839006
pii: S1054-139X(21)00096-3
doi: 10.1016/j.jadohealth.2021.02.011
pmc: PMC8403620
mid: NIHMS1678587
pii:
doi:
Substances chimiques
Nicotine
6M3C89ZY6R
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
447-456Subventions
Organisme : NCI NIH HHS
ID : P01 CA200512
Pays : United States
Informations de copyright
Copyright © 2021 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.
Références
JAMA Pediatr. 2020 Aug 1;174(8):797-800
pubmed: 32364581
Addict Behav. 2012 Jul;37(7):866-70
pubmed: 22464872
Nicotine Tob Res. 2020 Apr 21;22(5):647-654
pubmed: 30820566
Nicotine Tob Res. 2016 Jul;18(7):1596-605
pubmed: 26764258
Addiction. 2021 Jan;116(1):139-149
pubmed: 32533631
Nicotine Tob Res. 2017 Dec 13;20(1):3-11
pubmed: 27798090
Can J Public Health. 2015 Oct 09;106(6):e408-12
pubmed: 26680433
MMWR Surveill Summ. 2019 Nov 06;68(12):1-22
pubmed: 31805035
Ann Am Thorac Soc. 2014 Feb;11(2):231-5
pubmed: 24575992
PLoS One. 2018 Aug 10;13(8):e0200827
pubmed: 30096141
Eval Health Prof. 2014 Jun;37(2):147-55
pubmed: 24492245
Prev Med. 2020 Nov;140:106183
pubmed: 32603797
J Epidemiol Community Health. 2006 Jan;60(1):7-12
pubmed: 16361448
Am J Public Health. 2019 Mar;109(3):465-471
pubmed: 30676800
BMC Med Res Methodol. 2017 Dec 6;17(1):162
pubmed: 29207961
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2035-42
pubmed: 15598758
Addiction. 2017 Jan;112(1):8-17
pubmed: 27109256
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):629-633
pubmed: 29879097
BMJ. 2019 Jun 20;365:l2219
pubmed: 31221636
Ann N Y Acad Sci. 2012 Feb;1248:107-23
pubmed: 22092035
Tob Control. 2005 Jun;14(3):181-5
pubmed: 15923468
J Psychopharmacol. 2013 Jan;27(1):13-8
pubmed: 23035032
Tob Control. 2020 May;29(Suppl 3):s139-s146
pubmed: 32321847